Protagenic Therapeutics, Inc.\new Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
Protagenic Therapeutics, Inc.\new (PTIX) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $104.20 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-04-07.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2022-04-07
- Protagenic Therapeutics, Inc.\new adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2020-06-30 was $15.00K.
- Protagenic Therapeutics, Inc.\new adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2020-03-31 was $89.20K.
- Protagenic Therapeutics, Inc.\new adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2020 was $104.20K, a 74.08% decline from fiscal 2019.
- Protagenic Therapeutics, Inc.\new adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2019 was $402.00K.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 6 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|---|---|
| 2020-12-31 | $104.20K 10-K · filed 2022-04-07 | ||
| 2020-06-30 | $15.00K 10-Q · filed 2021-11-15 | $104.20K derived: sum of 2 quarters · filed 2021-11-15 | |
| 2020-03-31 | $89.20K 10-Q · filed 2021-11-15 | ||
| 2019-12-31 | $402.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |